Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Tough-to-Treat lung cancer: targeted pill takes on standard chemo

NCT ID NCT05132075

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new oral drug, JDQ443, against the standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It's for adults whose cancer has worsened after trying standard treatments like platinum-based chemo and immunotherapy. The main goal is to see if JDQ443 can keep the cancer from growing for longer than the standard chemo can.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    CABA, Buenos Aires, C1414DRK, Argentina

  • Novartis Investigative Site

    Pilar, Buenos Aires, B1629AHJ, Argentina

  • Novartis Investigative Site

    Auchenflower, Queensland, 4066, Australia

  • Novartis Investigative Site

    South Brisbane, Queensland, 4101, Australia

  • Novartis Investigative Site

    Montreal, Quebec, H4A 3J1, Canada

  • Novartis Investigative Site

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100010, China

  • Novartis Investigative Site

    Fuzhou, Fujian, 350014, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510030, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, 150081, China

  • Novartis Investigative Site

    Changsha, Hunan, 410013, China

  • Novartis Investigative Site

    Shengyang, Liaoning, 110042, China

  • Novartis Investigative Site

    Jinan, Shandong, 250117, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310003, China

  • Novartis Investigative Site

    Chongqing, 400042, China

  • Novartis Investigative Site

    Turku, FI-20521, Finland

  • Novartis Investigative Site

    Athens, GR, 115 27, Greece

  • Novartis Investigative Site

    Athens, 11526, Greece

  • Novartis Investigative Site

    Heraklion Crete., 715 00, Greece

  • Novartis Investigative Site

    Hong Kong, 999077, Hong Kong

  • Novartis Investigative Site

    Kowloon, 999999, Hong Kong

  • Novartis Investigative Site

    Budapest, 1121, Hungary

  • Novartis Investigative Site

    Reykjavik, IS-101, Iceland

  • Novartis Investigative Site

    Jaipur, Rajasthan, 302019, India

  • Novartis Investigative Site

    Delhi, 110085, India

  • Novartis Investigative Site

    Lucca, LU, 55100, Italy

  • Novartis Investigative Site

    Aviano, PN, 33081, Italy

  • Novartis Investigative Site

    Roma, RM, 00128, Italy

  • Novartis Investigative Site

    Amman, 11941, Jordan

  • Novartis Investigative Site

    Ed Daoura, 90375, Lebanon

  • Novartis Investigative Site

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Novartis Investigative Site

    Mexico City, 06760, Mexico

  • Novartis Investigative Site

    Matosinhos Municipality, 4454-513, Portugal

  • Novartis Investigative Site

    Porto, 4100-180, Portugal

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, 400015, Romania

  • Novartis Investigative Site

    Ljubljana, 1000, Slovenia

  • Novartis Investigative Site

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Oviedo, Principality of Asturias, 33011, Spain

  • Novartis Investigative Site

    Córdoba, 14004, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Tainan, 70403, Taiwan

  • Novartis Investigative Site

    Bangkok, 10330, Thailand

  • Novartis Investigative Site

    Adana, Adana, 01140, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Bilkent-Cankaya, 6800, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Fatih, 34093, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Pendik, 34899, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Yenimahalle, 06500, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, 06680, Turkey (Türkiye)

  • Novartis Investigative Site

    Hanoi, 300000, Vietnam

  • Valley Medical Center Research

    Renton, Washington, 98055, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER